Curium to buy Lantheus in radiopharma deal worth up to $8B
What's the deal? CuriumDealroom has a profile for this one. Try Dealroom →, a global radiopharmaceutical company, has agreed to acquire US-based Lantheus HoldingsDealroom has a profile for this one. Try Dealroom → in a cash deal valued at up to $8 billion. Lantheus will merge with a subsidiary of Curium US Holdings, with shareholders receiving $102.50 per share at closing plus Contingent Value Rights (CVRs) worth up to $12 per share. Lantheus' board unanimously approved the transaction.
How the price breaks down: The $114.50 top-end per-share figure represents a 38% premium to Lantheus' unaffected 60-day volume-weighted average price and a 21% premium to its unaffected closing price as of May 21, 2026 — the last trading day before the first media report of a potential sale. The CVRs pay out only if Lantheus' products hit specified commercial milestones through 2030.
What each side brings: Curium develops, manufactures, and supplies radiopharmaceuticals used to diagnose and treat cancer. Lantheus focuses on radiodiagnostics, including an F18-isotope prostate diagnostics franchise plus neurology and echocardiography imaging.
What's the endgame? The combined company would span both diagnostics and therapeutics, serving oncology, neurology, and cardiology patients in more than 70 countries. "This combination unlocks an opportunity that neither company could achieve alone," said Renaud Dehareng, chief executive officer of CuriumDealroom has a profile for this one. Try Dealroom → Group.
Why now? Curium says it has spent years building a theranostics platform by expanding manufacturing and advancing its radioligand therapy pipeline. Lantheus adds US commercial infrastructure and marks Curium's entry into the US market for neurology and echocardiography diagnostics.
The signal: Radiopharmaceuticals — which pair diagnostic imaging with targeted radiation therapy — are drawing major consolidation as companies race to build end-to-end platforms. The deal reflects a push to combine diagnostics and therapeutics under one roof, betting that scale across isotopes, geographies, and clinical areas is the way to win.
Read more: finanznachrichten.de
Image credit: Muffet
